Hims & Hers misses revenue estimates as strategy shift hits sales - Reuters

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQanhQZGhFWml1WURBSEhTdnJYU0RKR2lLdDdCV3phSDc5Q2VGa2RMRFRvU1BNRkVrQ3RrV3Q3T000aG9kdlg2NS1QU0xiMGpwZHlNUUdlSXZBQ3dvOE12Y0R0eXlabFpFUG9iTk8wdHIzQlJpZVQ2VEgzd3B4eWNfM1RBT200LVlUUnJFVks2SFpJU0FmSXc?oc=5" target="_blank">Hims & Hers misses revenue estimates as strategy shift hits sales</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

Hims & Hers Health raised its 2026 revenue forecast, betting on increased sales for its personalized healthcare offerings. The company now expects annual revenue between $2.8 billion and $3 billion, compared to its previous forecast of $2.7 billion to $2.9 billion.

Hims & Hers reported a net loss of $92.1 million in Q1 2026, primarily due to a shift in revenue recognition for certain weight-loss offerings, including the Hers brand, resulting from a change to shorter shipping cadences.

Hims & Hers reported Q1 2026 revenue of $608 million, a 4% year-over-year increase, and raised its full-year 2026 revenue guidance to a range of $2.8 billion to $3.0 billion, up from the previous forecast of $2.7 billion to $2.9 billion.

Hims & Hers Health, Inc. reported its first-quarter 2026 financial results, including revenue of approximately $608 million, a 4% year-over-year increase, and raised its full-year 2026 revenue guidance to a range of $2.8 billion to $3.0 billion.

Hims & Hers has undergone a significant business model shift, moving from a high-margin manufacturer to a lower-margin distributor, following regulatory challenges and a patent infringement lawsuit from Novo Nordisk.